2. Molecular Cancer Targets Wester H Clin Cancer Res 2007;13:3470-3481

3. Strengths of PET in Oncology 1. Improved Tumor Detection Only PET shows malignant intra-thoracic LN 2. Therapy Response Evaluation Lymphoma Ovarian carcinoma 3. Tumor Characterisation PET Baseline CT post R/ CT baseline Hypoxia Tumour Vasculature PET post R/ Wester, Clin Cancer Res 2007 4. Stromal Characterisation Bergers & Benjamin, Nat Rev Cancer 2003Carroll & Ashcroft, Exp Rev Mol Med, 2005

4. Characterisation of Cancer Hallmarks Hanahan & Weinberg, Cell 2000 Wester H Clin Cancer Res 2007 αVβ6 - 5nm affinity ligand Deroose et al., 2010, to be submitted Hausner et al.,Cancer Res 2009 Bauwens et al., 2009, abstract Interreg Apoptosis Imaging ApoptosisNo Apoptosis Imaging Angiogenesis Growth Receptor Imaging Dijkers et al, JNM 2009: Her2/neu Proliferation Imaging Imaging TGF-β signalling Kang et al, PNAS 2005 Imaging Tissue invasion NormalBlockage Imaging Metastasis Deroose et al., JNM 2007 Hanahan and Weinberg, Cell 2000

5. Novel PET Tracers for Cancer Diagnosis Ovarian carcinoma CT: Normal PET: Malignant Lymph Node FDG-PET /CT: Current State of the art BUT … FDG is not tumor specific Some tumors do not accumulate FDG Need for assessement of non- cytoreductive therapies Better Cancer Staging with FDG-PET/CT Evaluation of Novel 68 Ga-Labeled Receptor L igand PET/CT to Detect Ovarian Cancer http://www.enzolifesciences.com/ Folate Receptor (FR) Fisher et al, JNM 2008 FR Scintigraphy 68 Ga-FR Ligand First in man Dosimetry 30 patients Correlation with post-op histology Malignant LN CT: Normal CT PET PET/CT Malignant LN Evaluation of 11 C-Choline PET/CT in Locally Advanced Prostate Cancer

6. PET and Therapy Response Assessement FDG-PET /CT: Current State of the art in lymphoma Therapy Response Evaluation with FDG-PET/CT Baseline Post R/ Residual Mass Cured PET CT Baseline Post R/ BUT … FDG is not tumor specific Some tumors do not accumulate FDG Response without complete remission in solid tumors Need for assessement of non-cytoreductive therapies Assessement of 90Y-DOTATOC Peptide R eceptor Radiation Therapy with 68GA-DOTATOC PET/CT Baseline Post R/ SS Receptor in NET www.ihcworld.com “Theranostic” 68Ga/90Y-DOTATOC 68 Ga-DOTATOC PET/CT Post R/ Assessement of Anti-Angiogenic Therapy with Angiogenesis PET Deroose et al., 2010, to be submitted Bevacuzimab Baseline Cancer Bloodvessel Ligand Vessel PET

7. Multicenter Evaluation of PET as Response Predictor for Anti- EGFR Therapy in Metastatic Colorectal Cancer Van Cutsem et al, NEJM 2009 Prospective, multicenter trial to asses response to Cetuximab with PET 5 PET centers Tracer Production in Leuven

8. Ongoing Projects in Oncology Diagnostic performance of Choline PET in Prostate Cancer TR to Anti-angiogenic drugs in Colorectal Cancer TRE – RT planning in Colorectal Cancer TR to Anti-angiogenic Drugs in Colorectal Cancer Novel PET Tracer for Ovarian Cancer TRE to Medi551 in Non-Hodgkin Lymphoma (NHL) TRE to Proteasome Inhibitors in NHL TRE to Monoclonal Antibody in HL TRE to Monoclonal Antibody in NHL TRE to Anti-hormonal Therapy in Endometrial Cancer TRE to Small Molecule Her2Neu TKI in Breast Cancer TRE to Small Molecule Aurora Kinase Inhibitors in Sarcoma TRE to Multitarget Small Molecule TKI in Sarcoma TRE in NET after Peptide Receptor Radiation Therapy TRE in Pediatric Hodgkin’s Lymphoma (HL) Therapy Response Evaluation (TRE) in Lung Cancer (NSCLC) Academic Commercial